Sitagliptin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Type 2 diabetes mellitus
Adult: As an adjunct to diet and exercise to improve glycaemic control: Monotherapy or in combination with other antidiabetic agents: 100 mg once daily.
Suy thận
ESRD requiring haemodialysis or peritoneal dialysis: 25 mg once daily; may be given without regard to the timing of dialysis. eGFR <30 mL/min/1.73 m2: 25 mg once daily. eGFR ≥30 to <45 mL/min/1.73 m2: 50 mg once daily.
Cách dùng
May be taken with or without food.
Chống chỉ định
Hypersensitivity.
Thận trọng
Patient with history of pancreatitis, heart failure, or history of serious hypersensitivity reaction (e.g. angioedema) with other DPP-4 inhibitors. Patient undergoing periods of stress (e.g. trauma, infection, fever, surgery). Not indicated for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis. Moderate to severe (eGFR <45 mL/min/1.73 m2) renal impairment, including ESRD requiring haemodialysis or peritoneal dialysis. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hypoglycaemia (particularly in combination with sulfonylureas or insulins); worsening renal function, including acute renal failure (may require dialysis); severe and disabling arthralgia, bullous pemphigoid.
Gastrointestinal disorders: Constipation, vomiting, mouth ulceration, stomatitis.
Musculoskeletal and connective tissue disorders: Myalgia, back pain.
Nervous system disorders: Headache, dizziness.
Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, upper respiratory tract infection, interstitial lung disease.
Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus.
Potentially Fatal: Acute pancreatitis including haemorrhagic or necrotising pancreatitis, serious hypersensitivity reactions (e.g. anaphylaxis, angioedema, cutaneous vasculitis, exfoliative skin conditions including Stevens-Johnson syndrome).
Thông tin tư vấn bệnh nhân
This drug, particularly when taken in combination with other certain antidiabetics, may impair the patient's ability to concentrate and react due to hypoglycaemia; if affected, do not drive or operate machinery.
Chỉ số theo dõi
Obtain renal function before treatment initiation and periodically thereafter. Monitor HbA1c (at least twice yearly in patients with stable glycaemic control; quarterly in patients not meeting therapy goals or with changes in treatment); serum glucose. Assess for signs and symptoms of pancreatitis, heart failure, and hypersensitivity reactions; development of erosions or blisters.
Tương tác
Increased risk of hypoglycaemia when coadministered with sulfonylureas (e.g. glipizide, glimepiride) and insulins; consider lowering the dose of insulins or sulfonylureas. May slightly increase the serum concentration of digoxin.
Tác dụng
Description: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by enhancing the levels and prolonging the effects of active incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones regulate glucose homeostasis and are rapidly inactivated by the DPP-4 enzyme. Both GLP-1 and GIP increase insulin synthesis and release from pancreatic β cells by intracellular signalling pathways involving cyclic AMP, while GLP-1 lowers glucagon secretion from pancreatic α cells resulting in lower hepatic glucose production. Sitagliptin prevents the hydrolysis of incretin hormones caused by DPP-4 enzyme, thereby increasing and prolonging active incretin levels that elevate insulin release and decrease glucagon concentrations in the circulation (glucose-dependent manner).
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: Approx 87%. Time to peak plasma concentration: 1-4 hours.
Distribution: Volume of distribution: Approx 198 L. Plasma protein binding: 38%.
Metabolism: Minimally metabolised primarily by CYP3A4, and to a lesser extent by CYP2C8 isoenzyme into inactive metabolites.
Excretion: Mainly via urine (87%; approx 79% as unchanged drug, 16% as metabolites); faeces (13%). Terminal elimination half-life: Approx 12.4 hours.
Đặc tính

Chemical Structure Image
Sitagliptin

Source: National Center for Biotechnology Information. PubChem Database. Sitagliptin, CID=4369359, https://pubchem.ncbi.nlm.nih.gov/compound/Sitagliptin (accessed on Jan. 22, 2020)

Bảo quản
Store between 15-30°C.
Phân loại MIMS
Thuốc trị đái tháo đường
Phân loại ATC
A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Tài liệu tham khảo
Anon. Sitagliptin Phosphate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 20/05/2021.

Anon. Sitagliptin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 20/05/2021.

Buckingham R (ed). Sitagliptin Phosphate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/05/2021.

Januvia (Merck Sharp & Dohme [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 20/05/2021.

Januvia 100 mg Film-Coated Tablets (Merck Sharp & Dohme [UK] Limited). MHRA. https://products.mhra.gov.uk. Accessed 20/05/2021.

Januvia Film-Coated Tablet (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 20/05/2021.

Joint Formulary Committee. Sitagliptin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/05/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Sitagliptin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Sitaglo 100
  • Sitaglo 50
  • Sitagibes 50/Sitagibes 100
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in